Description: ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
Home Page: www.metherapeutics.com
177 Robson Street
Vancouver,
BC
V6B 0N3
Canada
Phone:
236-516-7714
Officers
| Name | Title |
|---|---|
| Dr. Salim Dhanji Ph.D. | CEO & Director |
| Mr. Quinn Martin C.A., CPA | Chief Financial Officer |
| Mr. Jamil Kassam | Corporate Secretary |
| Mr. Karim F. Lalji M.S., MS, SM | Chief Business Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | August |
| Full Time Employees: | 0 |